Boston Scientific Corporation (BSX – Q2FY20) – Positive impact of Vertiflex acquisition on revenue.

in , on September 30, 2020

Boston Scientific Corporation| will be launching LUX-Dx implantable cardiac monitor, which will offer a seamless patient interface and back-end monitoring. It will have the ability to be programmed remotely and have event detection settings adjusted without an in person visit.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q2FY20 Results – Overview
– 1HFY20 Results – Overview.
– Q2FY20 – Segment Performance
– Q2FY20 – New Developments
– Conclusion
– GAAP to Non-GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competitors
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 47

Release Information

  • Released
    :

    September 30, 2020

  • Last Updated
    :

    September 30, 2020